Medtronic announces partnership with biointellisense for exclusive u.s. distribution of multi-parameter wearable for continuous remote patient monitoring from in-hospital to home

Partnership reflects commitment to patient safety; biobutton® wearable offers up to 1,440 vital signs measurements daily, monitoring patients transitioning from higher to lower acuity settings technology complements the medtronic patient monitoring business' healthcast™ intelligent patient manager portfolio designed for connectivity, visualization, remote patient monitoring, and now, wearables dublin , aug. 31, 2022 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today announced it has entered into a strategic partnership with biointellisense, a continuous health monitoring and clinical intelligence company, for the exclusive u.s. hospital and 30-day post-acute hospital to home distribution rights of the biobutton® multi-parameter wearable for continuous, connected monitoring. the partnership enables the medtronic patient monitoring business to offer access to a medical grade device that provides continuous vital sign measurements of general care patients in-hospital as well as post-discharge.
MDT Ratings Summary
MDT Quant Ranking